Mehmet KILIÇ, Ali COŞKUN, Hakan BULUŞ, Alper YAVUZ, Barış MORKAVUK, Muzaffer AKKOCA

Klatskin tümörlerinde güncel tedavi yaklaşımları

Hiler kolanjiokarsinom ilk olarak 1965 yılında Klatskin tarafından tanımlanmış, safra yolları epitelinden kaynaklanan nispeten nadir görülen bir tümördür. Kolanjiokarsinom genellikle yaşamın 6. dekadında ve erkeklerde biraz daha sıklıkla rastlanmaktadır. Klatskin yada Kolanjiokarsinomların etyolojisi tam olarak bilinmemekte ancak endüstriyel toksinler, parazitik infeksiyonlar, safra kanalı malformasyonları, caroli hastalığı, primer sklerozan kolanjit gibi predispozan ve çevresel faktörlerin etyolojide rol oynadığı düşünülmektedir. Hilar kolanjiokarsinomlarda karaciğerdeki safranın %30’unun drene olabilmesi halinde sarılık görülmeyebilir ancak bu drenaj sağlanmadığı takdirde kaşıntı, kolanjit ve hepatik apse oluşumu gibi sonuçlar ortaya çıkabilmektedir. Bu çalışmadaki amaç; hiler kolanjiokarsinomun cerrahi tedavisindeki ilerlemeleri literatür eşliğinde vurgulamaktır.

Current treatment approaches for Klatskin tumors

Hilar cholangiocarcinoma, is a relatively rare tumor arising from the bile ducts, was first described by Klatskin in 1965. It usually ocurs in adults in their sixth decade of life and there is slight male predominance. It is most frequently located in the confluence of the hepatic ducts, where it is called hilar cholangiocarcinoma or Klatskin tumor. The etiology of hilar cholangiocarcinoma remains unknown but there are predisposing conditions and environmental risk factors such as primary sclerosing cholangitis, Caroli disease, bile duct malformations, industrial toxins and parasitic infections. If 30% of the liver is drained jaundice can be relieved, but the presence of undrained bile ducts may result in pruritus and a continued risk of cholangitis and hepatic abscess. This study aimed to emphasize the current treatment approaches for hilar cholangiocarcinoma in the light of literature.

PDF

___

1.Altemeier WA, Gall EA, Zinninger MM, Hoxworth P1. Sclerosing carcinoma of the major intrahepatic bile ducts. Arch Surg 1957;75:450-461.
2.Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med 1965;38:241-56.
3.Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-1314.
4.Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10:77-82.
5.Brandsaeter B, Isoniemi H, Broomé U, et al: Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004;40:815–822.
6.Flanigan DP: Biliary carcinoma associated with biliary cysts. Cancer 1977 Aug; 40(2):880–883.
7.Yamamoto S, Kubo S, Hai S, et al: Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004;95:592–595.
8.Vogl T.J. ,Schwarz W.O. ,Helter M. Staging of Klatskin Tumors (Hilar Cholangicarcinomas):comparison of MR cholangiography,MR imaging and ERCP.Eur Radiol (2006) 16:2317-2325.
9.Park HS, Lee JM, Choi JY, Lee MW, Kim HJ, Han JK, et al. Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography. AJR Am J Roentgenol 2008;190:396-405.
10.Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009;16:14-22.
11.Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992;215:31-38.
12.Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III A. Perihilar Bile Ducts. In: AJCC Cancer Staging Handbook. 7th ed. Chicago, IL: Springer; 2010:718.
13.Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-517.
14.Michelle L. DeOliveira, Richard D. Schulick, Yuji Nimura, Charles Rosen et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 2011;53:1363-1371.
15.Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005 May;241(5):703-12.
16. Li SQ, Liang LJ, Hua YP, et al. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma. Chin Med J 2009; 122: 2286-2291.
17.Han SS, Jang JY, Lee KU, Kim SW. Actual long-term outcome of Klatskin’s tumor after surgical resection. Hepatogastroenterology;2008 Nov-Dec;55(88):1986-92.
18.Aydin U, Yedibela S, Yazici P, Aydinli B, Zeytunlu M, Kilic M, Coker A. A new technique of biliary reconstruction after “high hilar resection” of hilar cholangiocarcinoma with tumor extension to secondary and tertiary biliary radicals. Ann Surg Oncol. 2008 Jul;15(7):1871-9.
19.Friman S, Foss A, Isoniemi H, et al: Liver transplantation for cholangiocarcinoma selection is essential for acceptable results. Scand J Gastroenterol 2010 Nov 15.
20.Iwatsuki S, Todo S, Marsh JW, Madariaga JR, Lee RG, Dvorchik I, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998; 187:358–64.
21.Ballinger AB, McHugh M, Catnach SM, Alstead EM, Clarck ML. Symptom relief and quality of life after stenting for malignant bile duct obstruction. Gut 35: 467-70, 1994.
22.Kaassis M, Boyer J, Dumas R, et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc 57: 178-82, 2003.
23.Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosisn and treatment of cholangiocarcinoma. The Oncologist 9: 43-57, 2004.
24.Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WMC, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51(suppl): vi1-vi9, 2002.
25.Ortner MA, Liebetruth J, Schreiber S, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998;114:536-542.
26.Talreis JP, Kahaleh M. Photodynamic therapy for cholangiocarcinoma. Gut liver; 2010 Sep;4 Suppl 1:S62-6. Epub 2010 Sep 10.